Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Overview

This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study

Full Title of Study: “An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
  • Study Primary Completion Date: October 13, 2015

Interventions

  • Biological: ACZ885

Arms, Groups and Cohorts

  • Experimental: canakinumab
    • Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)

Clinical Trial Outcome Measures

Primary Measures

  • The Percentage of Participants Without Disease Relapse as Determined by the Physician’s Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin Disease and Serological Inflammation Markers.
    • Time Frame: Week /80, 104, 128, and 152 (A minimum of 6 months and maximum of 24 months)
    • Disease relapse following complete response is defined as inflammation markers: C-Reactive Protein (CRP) and/or Serum Amyloid A (SAA) result > 30 mg/L AND Physician’s Global Assessment of Autoinflammatory Disease Activity > minimal or Physician’s Global Assessment >= minimal AND Skin Disease Assessment > minimal. Physician’s Global Assessment of Autoinflammatory Disease Activity and Skin Disease Assessment (urticarial skin rash) are completed by the investigator using a 5 point rating scale: absent, minimal, mild, moderate and severe.

Secondary Measures

  • Immunogenicity of Canakinumab (ACZ885). Number of Participants With Anti-canakinumab Antibodies
    • Time Frame: minimum of 6 months and maximum of 24 months
    • Immunogenicity assessment included determination of anti-canakinumab (ACZ885) antibodies in serum samples using BIAcore system, with detection based on surface plasmon resonance technique.
  • Change From Baseline (Core Study Baseline) in C–Reactive Protein (CRP) and Serum Amyloid A (SAA) Concentrations
    • Time Frame: Week 0, 80, 104, 128 and 152, last assessment
    • CRP and SAA were used as serologic inflammatory markers. The target level concentrations for CRP and SAA was ≤15 mg/L and ≤10 mg/L, respectively. Negative change in concentration of inflammatory markers indicated improvement.
  • Frequency Counts of Physician’s Global Assessment of Autoinflammatory Disease and Skin Disease
    • Time Frame: minimum of 6 months and maximum of 24 months
    • Participants were assessed based by physician on Physician’s Global Assessment measured on a 5–point scale for auto inflammatory disease activity as: 0 = None/absent; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe
  • Number of Vaccination Cases With Protective Antibody Levels Following Immunization With Inactivated Vaccines
    • Time Frame: pre-vaccine dose, Day 28 post-vaccine
    • Participants who received any inactivated vaccines during the study were assessed for their ability to attain protective antibody levels against the vaccine (antigen) post immunization. Participants vaccinations were not assessed for a response if the antibody titre was already sufficient at pre-dose and maintained during the study.

Participating in This Clinical Trial

Inclusion Criteria

1. Patients who completed the core CACZ885D2307 study (a patient is defined as having completed the core study if they completed the study up to and including the EOS visit with no major protocol deviations in the core). 2. Male and female patients that are ≥ 1 year of age at the time of the roll-over visit. 3. Parent or legal guardian written informed consent must be obtained before any assessment in the extension CACZ885D2307E1 study is performed. Exclusion criteria:

1. Patients for who continued treatment in the CACZ885D2307E1 extension study is not considered appropriate by the treating physician. 2. Patients who discontinued from the core CACZ885D2307 study Other protocol-defined inclusion/exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 4 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.